Oral News and Research

RSS

New skin atlas maps over one million cells across the human body

Mount Sinai researchers have published the first organ-wide human skin spatial atlas from across the body.

25 Mar 2026

Can collagen supplements really improve your skin?

Investigating collagen peptides, this review explores their role in skin aging, assessing clinical evidence and the mechanisms behind their potential benefits.

25 Mar 2026

Drug-releasing stitches aim to reduce inflammation and improve healing

Deep cuts from accidents or surgeries require stitches, typically followed by oral anti-inflammatory medications like ibuprofen. While these medications help with pain, they don't act specifically on the wounds.

24 Mar 2026

Snus linked to gum damage but tooth decay risk unclear

Snus is clearly linked to damage to the gums. The connection to tooth decay, however, remains unclear, according to a systematic review. When it comes to white snus, more studies are needed.

23 Mar 2026

New cholesterol guidelines emphasize earlier risk assessment and prevention

New national guidance for managing cholesterol and other blood lipids emphasizes earlier risk assessment, more personalized treatment, and long-term prevention—including, in some cases, treatment beginning as early as age 30.

23 Mar 2026

AI-driven atlas reveals how mouth fibroblasts regulate structural immunity

Researchers at VCU Massey Comprehensive Cancer Center are leading an international study that advances the understanding of the immunoregulatory nature of human tissues, offering breakthrough insights into how fibroblasts serve as the core regulators of structural immunity in the mouth.

23 Mar 2026

Firmer potatoes lower post-meal blood sugar spikes

Minimally cooked potatoes may reduce blood sugar spikes, but benefits are short-lived and specific to certain populations, as shown in recent research.

23 Mar 2026

Replacing sedentary time improves insulin resistance in adolescents

Adolescents who replaced just half an hour of sedentary behaviors, such as sitting on the couch or spending time at the computer, each day for moderate-to-vigorous physical activity or sleep may lower their insulin resistance, a key factor in preventing the development of Type 2 diabetes, according to preliminary research presented at the American Heart Association's EPI|Lifestyle Scientific Sessions 2026.

23 Mar 2026

Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials

Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in people with early symptomatic, amyloid-positive Alzheimer’s disease. Semaglutide was generally consistent with its known safety profile and showed some biomarker changes, but these did not translate into clinical benefit.

22 Mar 2026

L.B. Bohle at Interphex 2026

At INTERPHEX 2026, L.B. Bohle presents cutting-edge solutions for oral solid dose production, focusing on continuous manufacturing and process optimization.

From L.B. Bohle Maschinen und Verfahren GmbH 20 Mar 2026

LGM Pharma expands U.S. manufacturing, bringing total investment to $15M across Texas and Colorado sites

LGM Pharma, a leading provider of tailored API sourcing, contract analytical testing, and CDMO services for the full drug product lifecycle, today announced the second phase of its CDMO growth strategy, committing an additional $9 million to its facilities in Rosenberg, Texas, and Colorado Springs, Colorado.

From LGM Pharma 19 Mar 2026

Combination therapy shows promise for leptomeningeal metastasis in breast cancer

Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

18 Mar 2026

One-dose oral treatment may be the simplest weapon against sleeping sickness

Sleeping sickness has been killing people across Africa for generations. A disease with no vaccine, spread by the bite of a tsetse fly, it was once treated with injections of an arsenic derivative, a cure that could be as dangerous as the illness itself.

17 Mar 2026

How one antibiotic dose can reshape your gut microbiome for years

Long-term registry-linked analysis of nearly 15,000 adults shows that antibiotic use is associated with persistent changes in gut microbiome diversity and composition for up to 4–8 years. These effects vary by antibiotic class, with clindamycin, fluoroquinolones, and flucloxacillin showing the strongest and most sustained associations.

17 Mar 2026

Investigational oral therapy shows safety and potential benefits in ALS trial

In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people living with amyotrophic lateral sclerosis (ALS), with exploratory findings suggesting target engagement and potential clinical benefits.

16 Mar 2026

Largest review finds no mental health benefits of medicinal cannabis

A landmark Lancet Psychiatry paper published today – the largest-ever review of the safety and efficacy of cannabinoids across a range of mental health conditions – found no evidence that medicinal cannabis is effective in treating anxiety, depression or post-traumatic stress disorder (PTSD).

16 Mar 2026

Clinical trial tests a newer, targeted therapy for IDH mutant astrocytoma

A new clinical trial led by the Alliance for Clinical Trials in Oncology will investigate if a combination of drug therapies after radiation therapy improves outcomes for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma, a type of brain cancer.

16 Mar 2026

Why do some people respond better to GLP-1 drugs? Gut microbiome may hold clues

A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment outcomes. The authors conclude that microbiome changes seen during therapy are most likely driven by diet, behavior, and weight loss, although microbial profiling may eventually help predict patient responses.

15 Mar 2026

Updated guideline emphasizes earlier treatment for high cholesterol

The American College of Cardiology (ACC), the American Heart Association and nine other leading medical associations, today issued an updated guideline for the management of dyslipidemia-abnormal levels of one or more types of lipids or lipoproteins in the blood, including cholesterol and triglycerides.

13 Mar 2026

Swapping red meat for plant-based meat rapidly lowers a key heart risk metabolite, trial finds

A randomized crossover trial found that replacing red meat patties with processed plant-based meat alternatives for six days significantly lowered circulating trimethylamine N-oxide (TMAO), a gut-derived metabolite linked to cardiovascular risk. The plant-based phase also produced modest reductions in cholesterol markers but slightly increased weight and NT-proBNP, possibly due to higher sodium intake.

12 Mar 2026